EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Miscellaneous IGEA Pharma support Italian COVID-19 battle Hoofddorp, the Netherlands, 18 March 2020. IGEA Pharma (SIX: IGPH) today announced an explosion in the demand for dry aerosol devices in Italy as a result of the COVID-19 outbreak so severely affecting this country. IGEA operates in air and surfaces sanitization with aerosol technology-based devices following the understandings on the acquisition of privately held Medical Jet. Vincenzo Moccia, CEO of IGEA: "The proven action of our aerosol solutions together with Rely+On Virkon(R) in reducing a broad spectrum of viruses and bacteria is highly appreciated. We remain fully committed to contribute in solving the problems of contamination of the air and the surfaces in the environments with high infections and life-threatening risk". The demand for aerosol solutions in Italy increased by 20 times compared to historic demand. As a result, IGEA and Medial Jet are enhancing the production capacities. *** About IGEA IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl Contacts The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward-looking statements or to adapt them to future events or developments, except as may be required by law. End of ad hoc announcement |
Language: | English |
Company: | IGEA Pharma N.V. |
Siriusdreef 17 | |
2123 WT Hoofddorp | |
Netherlands | |
Phone: | +31 23 568 9494 |
E-mail: | info@igearesearch.com |
Internet: | www.igeapharma.nl |
ISIN: | NL0012768675 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1001235 |
End of Announcement | EQS Group News Service |
1001235 18-March-2020 CET/CEST